Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial

IMPORTANCE: Three years of adjuvant imatinib mesylate therapy is associated with reduced recurrence rates and improved overall survival in patients with high-risk primary gastrointestinal stromal tumor (GIST) compared with patients who receive 1 year of treatment. The impact of a longer duration of...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA Oncol
Main Authors: Raut, Chandrajit P., Espat, N. Joseph, Maki, Robert G., Araujo, Dejka M., Trent, Jonathan, Williams, Toni Faith, Purkayastha, D. Das, DeMatteo, Ronald P.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2018
נושאים:
Original Investigation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440723/
https://ncbi.nlm.nih.gov/pubmed/30383140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4060
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים